Adjuvant Treatment with Alpha Interferon (IFN) for Patients at High Risk for Relapse after Allogeneic Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

被引：1
|
作者：
Bezerra, Evandro Dantas [1 ]
Radich, Jerald [2 ]
Flowers, Mary E. [2 ]
Chielins, Debbie [3 ]
Higano, Celestia [4 ]
机构：
[1] Univ Washington, Med, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA
[3] Seattle Canc Care Alliance, Oncol, Seattle, WA USA
[4] Univ Washington, Dept Med, Seattle, WA USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2018年 / 24卷 / 03期
关键词：
D O I：
10.1016/j.bbmt.2017.12.224
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
326
引用
收藏
页码：S238 / S238
页数：1
相关论文
共 50 条
  • [31] ALLOGENEIC MARROW TRANSPLANTATION (BMT) FOR CHILDREN WITH JUVENILE CHRONIC MYELOGENOUS LEUKEMIA (JCML)
    SMITH, FO
    SANDERS, JE
    ROBERTSON, KA
    GOOLEY, T
    SIEVERS, EL
    BLOOD, 1994, 84 (10) : A201 - A201
  • [32] CHRONIC MYELOGENOUS LEUKEMIA - CELL-CULTURES AFTER THERAPY WITH ALPHA-INTERFERON - (CML)
    CASTAGNOLA, C
    BONFICHI, M
    MORRA, E
    BRERA, C
    BERNASCONI, P
    LAZZARINO, M
    BERNASCONI, C
    EXPERIMENTAL HEMATOLOGY, 1992, 20 (06) : 782 - 782
  • [33] Genetic randomization of allogeneic BMT vs drug treatment in chronic myelogenous leukemia:: The German CML study III.
    Hehlmann, R
    Berger, U
    Hochhaus, A
    Reiter, A
    Pfirrmann, M
    Hasford, J
    Heimpel, H
    Hossfeld, DK
    Huber, C
    Kolb, HJ
    Löffler, H
    Pralle, H
    Queisser, W
    Gratwohl, A
    Tobler, A
    BLOOD, 2000, 96 (11) : 141A - 141A
  • [34] Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia
    Kantarjian, HM
    O'Brien, S
    Cortes, JE
    Giralt, SA
    Rios, MB
    Shan, JQ
    Giles, FJ
    Thomas, DA
    Faderl, S
    De Lima, M
    Garcia-Manero, G
    Champlin, R
    Arlinghaus, R
    Talpaz, M
    BLOOD, 2002, 100 (05) : 1590 - 1595
  • [35] ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC MYELOCYTIC-LEUKEMIA (CML) - PERSISTENCE OF A FEW PH+ MITOSES EARLY AFTER BMT IS NOT INDICATIVE FOR RELAPSE
    HINTERBERGER, W
    HAAS, O
    HOCKER, P
    POLLAK, C
    HAJEKROSENMAYR, A
    VOLCPLATZER, B
    KALLINGER, W
    KOLBABEK, H
    ALTH, G
    FISCHER, M
    GEISSLER, K
    LECHNER, K
    GADNER, H
    DEUTSCH, E
    BLUT, 1985, 51 (03): : 223 - 223
  • [36] Alfa-2-a interferon (IFN) reduces the cytogenetic relapse rate in patients who are PH negative but PCR positive for BC/ABL 6-12 months after allogeneic transplantation (alloT) for chronic myelogenous leukemia (CML).
    Higano, CS
    Chielens, DF
    Steffan, A
    Bryant, EM
    Flowers, ME
    Kadich, JP
    BLOOD, 2002, 100 (11) : 333B - 334B
  • [37] TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA WITH INTERFERON-ALPHA
    GUILHOT, F
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1991, 33 (02): : 200 - 201
  • [38] TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA BY ALPHA-INTERFERON
    GUILHOT, F
    M S-MEDECINE SCIENCES, 1991, 7 (05): : 453 - 459
  • [39] INTERFERON-ALPHA FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA
    THALER, J
    ACTA MEDICA AUSTRIACA, 1993, 20 (03) : 65 - 69
  • [40] PROLONGED EFFECT OF ALPHA-INTERFERON AFTER DISCONTINUANCE OF TREATMENT IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS
    ALIMENA, G
    MONTEFUSCO, E
    MANCINI, M
    DEFABRITIIS, P
    CEDRONE, M
    SANDRELLI, A
    MANDELLI, F
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1989, 43 (02) : 108 - 111
12345